IVAX GETS APPROVAL TO MARKET PAXENE IN CANADA.IVAX Corporation (AMEX AMEX See: American Stock Exchange :IVX), Miami, Fla., has received approval to market its proprietary anti-cancer drug, PAXENE (paclitaxel), in Canada for the treatment of AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy. Paclitaxel is marketed in the U.S. and elsewhere by Bristol-Myers Squibb under the trade name Taxol. "This approval of PAXENE(R) in Canada is another fine achievement for our company and builds upon approvals for this product in the European Union, Poland and the Czech Republic," said Phillip Frost, M.D., chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of IVAX Corporation. IVAX IVAX Industrial Vax (Dec Computer) also has an Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar (ANDA ANDA abbr. abbreviated new drug application ) pending in the United States for a generic form of Taxol(R) (paclitaxel), for which the company expects six months of generic marketing exclusivity upon approval in 2000. The U.S. market for Taxol(R) is expected to exceed $1 billion in 2000. IVAX Corporation, headquartered in Miami, Florida, is a holding company with subsidiaries engaged in the research, development, manufacture, and marketing of branded and generic pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets. For more information, visit www.ivax.com or call 305/575-6005. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion